top of page

TRAIL gene therapy + immune cell therapy

 Keihokai Ikebukuro Club

Compound TRAIL Gene Therapy

Compound TRAIL Gene Therapy

      _cc781905-5cde-319 4-bb3b-136bad5cf58d_ Using TRAIL gene therapy combined with activated NK cell therapy, the two treatment for maximum effect.

What is TRAIL?

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a kind of tumor necrosis factor (tumor necrosis factor, TNF). TRAIL binds to its receptor to initiate apoptosis signal transmission, selectively induces tumor cell apoptosis, and has no obvious damage to normal tissue cells. Combining drugs and cytokines can cooperate with TRAIL to induce tumor cell apoptosis. For most malignant tumors, TRAIL can significantly inhibit tumor growth and block cancer cell metastasis.

Compound TRAIL Gene Therapy Process

​Activated NK therapy

Activated NK therapy uses the patient's own immune cells and is suitable for most cancers. At the discretion of the physician, it may be used in combination with other treatments. NK cells are non-specific immune cells that attack virus-infected cells and cancer cells.

About 50 ml of blood is drawn, and after about two weeks in a sterile culture facility, it is cultured and activated by qualified culture technicians to increase the number of NK cells from hundreds to thousands of times. The cultured NK cells are then injected back into the patient's body by means of drips.    

Activated NK Therapy Process

αβT cell therapy

αβT cells are a type of T cells in lymphocytes. Since cancer cells can suppress the immune system, αβT cells help organize the immune environment in the body and enhance immunity.

About 40 milliliters of blood is drawn, cultured and activated by qualified culture technicians in a sterile culture facility that complies with regulations, and dripped back into the patient about two weeks later. αβT cells are more likely to affect the immune system than NK cells, and a small number of patients have fever after receiving it. It is recommended to accept the judgment and discussion of immunologists before deciding whether to accept αβT cell therapy.

αβT cellsTherapy process

Dendritic cell therapy

Through in vitro induction, the dendritic cells that have received antigen prompts or matured are infused back into the body, and the dendritic cells will first move to the lymph nodes (Figure ①).

Dendritic cells perform antigen-specific proliferation and activation of CTL cytokines and induction, proliferation and activation of Th1 in lymph nodes (Figure ②, ③).

The induced CTL will break away from the lymph node, move towards the tumor site and attack the cancer cells (Fig. ④).

Diagram of Dendritic Cell Therapy
Dendritic cells are induced and proliferated using tumor antigens or artificial antigens in the patient's body, and then injected back into the patient's body to obtainAntigen dendritic cells can activate CTL cells.

Clinic introduction


Comfortable and spacious clinic interior


Dean's introduction




Graduated from the Faculty of Pharmacy, Kyoto University in 1990
Graduated from the Faculty of Medicine, Kyoto Prefectural University of Medicine in 1997
       Tokyo Women's Medical University Hospital
         Yamanashi Prefectural Central Hospital
NTT East Kanto Hospital
2010 Ikebukuro Cancer Clinic opened
In 2014, the chairman of the medical corporation Huifengkai took office


①Priority is given to the physical condition of the patient

② Supported by highly specialized and cultivated skills

​③ Make the best treatment according to the patient’s condition

Clinic address

〒171-0022  Toyoshima-ku, Tokyo

Minami Ikebukuro 1-chome 25-11No. 15 No Hagi Biru 7F  


If you have any questions, please feel free to contact us through any of the methods below.

Name: *

Mailbox: *

Telephone: *




TW contact only: +886-90-5563-717

JP For emergency contact: +81-80-4276-3930


​JP Tel / Fax:  +81-92 -984-3200



LINE@ ID: @medicalsupporter


LINE & WeChat & Skype: medicalsupporter

  • Facebook
  • Instagram
bottom of page